Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.22 USD
Change Today +0.05 / 0.55%
Volume 38.6K
CGIX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Open
$9.24
Previous Close
$9.17
Day High
$9.41
Day Low
$8.90
52 Week High
05/5/14 - $14.19
52 Week Low
12/3/14 - $4.83
Market Cap
90.6M
Average Volume 10 Days
84.4K
EPS TTM
$-1.68
Shares Outstanding
9.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. The company offers microarray based testing, a microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer; and next generation sequencing testing, a proprietary next generation sequencing tests for the diagnosis and prognosis of genomic alterations in chronic lymphocytic leukemia, myeloma, and B-cell non-hodgkin's lymphomas. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutation analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides fluorescent in situ hybridization testing, an analysis of abnormalities at the chromosomal and gene levels; histology testing, a microscopic examination of stained tissue sections; and cytology testing, a non-gynecological fluid preparation for microscopic evaluations. Further, it offers IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various oncology-focused tests and laboratory services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. It also provides Expand Dx program for community hospital’s oncology diagnostic process; and consulting, guidance, and preparation of samples and clinical trial design. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

139 Employees
Last Reported Date: 03/16/15
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $260.3K
Vice President of Research & Development
Total Annual Compensation: $297.9K
Compensation as of Fiscal Year 2014.

cancer genetics inc (CGIX) Key Developments

Cancer Genetics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 11:00 AM

Cancer Genetics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 11:00 AM. Speakers: Panna Sharma, Chief Executive Officer, President and Director.

Cancer Genetics Increases Access to its Comprehensive Cancer Diagnostic Tests, Services Through Agreement with America's Choice Provider Network

Cancer Genetics, Inc. announced that it has executed an agreement with America's Choice Provider Network. Under the terms of the agreement, CGI's cancer diagnostic services will be available to more than 19 million domestic members covered by ACPN. The addition of America's Choice into the CGI network of healthcare providers allows CGI's growing clinical sales team to reach a much larger population of providers and their patients. Participation in provider networks, such as America's Choice, constitutes an integral part of CGI's multi-part access and reimbursement strategy. CGI's reimbursement strategy includes partnerships and collaborations with cooperative oncology study groups, targeted relationships with leading payers and insurance companies, and health economic and validation studies with thought leaders at leading medical institutions. Through these initiatives, the company believes it will be able to expand access to and ensure reimbursement for the company's unique genomic tests.

Cancer Genetics, Inc. Announces Consolidated Earnings Results for the Year Ended December 31, 2014

Cancer Genetics, Inc. announced consolidated earnings results for the year ended December 31, 2014. Fourth quarter 2014 revenues were USD 4.0 million, a 118% increase over fourth quarter 2013 revenues of USD 1.9 million, and 25% sequential growth over USD 3.2 million in the third quarter of 2013. Earnings on an adjusted basis during the fourth quarter was USD 4.7 million, or USD 0.49 per diluted share. Net loss for the quarter was USD 5.2 million, or USD 0.55 per diluted share, compared to a net loss of USD 2.5 million, or USD 0.37 per diluted share in the fourth quarter of 2013. For the year, the company reported revenue of USD 10,199,387 against USD 6,609,957 a year ago. Loss from operations was USD 19,209,086 against USD 8,461,583 a year ago. Loss before income taxes was USD 18,993,104 against USD 13,036,453 a year ago. Net loss was USD 16,642,919 or USD 1.80 per diluted share against USD 12,372,553 or USD 3.64 per diluted share a year ago. Adjusted loss was USD 16.2 million, or USD 1.71 per diluted share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $9.22 USD +0.05

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $33.16 USD +0.04
Genomic Health Inc $28.28 USD +1.21
NeoGenomics Inc $4.79 USD +0.26
Response Genetics Inc $0.30 USD -0.0001
Rosetta Genomics Ltd $3.48 USD -0.21
View Industry Companies
 

Industry Analysis

CGIX

Industry Average

Valuation CGIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit www.cancergenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.